Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation

Bone Marrow Transplant. 2008 Apr;41(8):749-51. doi: 10.1038/sj.bmt.1705974. Epub 2008 Jan 14.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Adult
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Cytomegalovirus / immunology
  • Cytomegalovirus / pathogenicity
  • Cytomegalovirus Infections / prevention & control*
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Leukocyte Reduction Procedures / methods
  • Lymphocyte Count
  • Lymphocytes / drug effects
  • Male
  • Middle Aged
  • Retrospective Studies
  • Transplantation Conditioning / methods*
  • Transplantation, Homologous / adverse effects

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Alemtuzumab